Stock AHPAU ORGANOGENESIS HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Organogenesis Holdings Inc. Nasdaq

Equities

AHPAU

KYG0726L1095

Delayed Nasdaq
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Organogenesis Holdings Inc. +1.51% +0.58%
05-13 Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating MT
05-10 Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup DJ

Evolution of the average Target Price on Organogenesis Holdings Inc.

Price target over the last 5 years

History of analyst recommendation changes

f29966fdd1161.DBV2PoWmy21Ov7CSA7_Ag26Fjw6gGKyvLm-j359vo8o.WH8ESLbJuwV67tfrdN6lyCL0yVzBSdnoSSr77u5exP9bRiRu_--6FBbT4Q~63c979735f77e4552c02f50896e612e0

Analyst Recommendations on Organogenesis Holdings Inc.

Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating MT
BTIG Raises Price Target on Organogenesis Holdings to $6 From $4, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Organogenesis to $3.50 From $3, Maintains Equalweight Rating MT
Hopes of rate peak, China turnaround lift stocks AN
Morgan Stanley Adjusts Price Target on Organogenesis Holdings to $3 From $5, Maintains Equal-Weight Rating MT
Morgan Stanley Starts Organogenesis Holdings at Equalweight With $5 Price Target MT
BTIG Upgrades Organogenesis to Buy From Neutral, Price Target is $10 MT
BTIG Downgrades Organogenesis Holdings to Neutral From Buy MT
Oppenheimer Downgrades Organogenesis Holdings to Perform From Outperform, Removes $14 Price Target MT
SVB Leerink Adjusts Organogenesis Holdings' Price Target to $20 from $26, Keeps Outperform Rating MT
ORGANOGENESIS : Oppenheimer Adjusts Organogenesis Holdings PT to $28 From $25 on Strong Q1 Beat and Raised Guidance, Maintains Outperform Rating MT
ORGANOGENESIS : Oppenheimer Adjusts Price Target on Organogenesis Holdings to $25 From $21, Keeps Outperform Rating MT
ORGANOGENESIS : SVB Leerink Adjusts Price Target on Organogenesis Holdings to $22 From $19, Maintains Outperform Rating MT
ORGANOGENESIS : Credit Suisse Raises Organogenesis Holdings' PT to $21 from $9, Expects Continued Success of Commercial Execution Strategy; Keeps Outperform Rating MT
ORGANOGENESIS : SVB Leerink Adjusts Organogenesis Holdings' Price Target to $13 From $10, Keeps at Outperform MT
ORGANOGENESIS : Oppenheimer Adjusts Price Target on Organogenesis Holdings to $13 From $9, Maintains Outperform Rating MT
ORGANOGENESIS : Credit Suisse Adjusts Organogenesis Holdings' Price Target to $9 from $8, Keeps Outperform Rating MT
ORGANOGENESIS : SVB Leerink Adjusts Organogenesis Holdings' Price Target to $10 From $9, Keeps at Outperform MT
ORGANOGENESIS : Credit Suisse Adjusts Organogenesis Holdings' Price Target to $8 from $7, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.75 USD
Average target price
4.667 USD
Spread / Average Target
+69.70%
High Price Target
6 USD
Spread / Highest target
+118.18%
Low Price Target
3 USD
Spread / Lowest Target
+9.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Organogenesis Holdings Inc.

Morgan Stanley
BTIG
Oppenheimer
SVB Leerink
Credit Suisse

Ratings for Organogenesis Holdings Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ORGO Stock
  4. AHPAU Stock
  5. Consensus Organogenesis Holdings Inc.